Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for gastrointestinal diseases. The company's flagship product candidate, VOQUEZNA, has demonstrated significant potential in late-stage clinical trials. Specifically, VOQUEZNA has completed Phase III trials for the treatment of erosive gastroesophageal reflux disease (GERD) and associated heartburn in adult patients. Furthermore, VOQUEZNA Triple Pak and VOQUEZNA Dual Pak have also concluded Phase III studies, targeting the eradication of Helicobacter pylori infections. The company's pipeline also includes VOQUEZNA and vonoprazan, which are being investigated for the treatment of heartburn related to non-erosive GERD and eosinophilic esophagitis in both adult and adolescent populations. Phathom's strategic focus is on addressing unmet medical needs within the gastroenterology space, leveraging its scientific expertise and clinical development capabilities to bring novel therapeutic options to patients suffering from these prevalent conditions. The company aims to establish a strong market presence by offering differentiated solutions that improve patient outcomes and quality of life.